| Literature DB >> 29599705 |
Abstract
The Fragile X Syndrome (FXS) is one of the most common forms of inherited intellectual disability in all human societies. Caused by the transcriptional silencing of a single gene, the fragile x mental retardation gene FMR1, FXS is characterized by a variety of symptoms, which range from mental disabilities to autism and epilepsy. More than 20 years ago, a first animal model was described, the Fmr1 knock-out mouse. Several other models have been developed since then, including conditional knock-out mice, knock-out rats, a zebrafish and a drosophila model. Using these model systems, various targets for potential pharmaceutical treatments have been identified and many treatments have been shown to be efficient in preclinical studies. However, all attempts to turn these findings into a therapy for patients have failed thus far. In this review, I will discuss underlying difficulties and address potential alternatives for our future research.Entities:
Keywords: E/I balance; FMR1; Fragile X Syndrome; autism spectrum disorders; behavior and cognition; microsatellite instability; mouse model; primates
Year: 2018 PMID: 29599705 PMCID: PMC5862809 DOI: 10.3389/fnmol.2018.00041
Source DB: PubMed Journal: Front Mol Neurosci ISSN: 1662-5099 Impact factor: 5.639
Figure 1The FXS world. The drawing illustrates factors influencing the disease. A characteristic of FXS is the presence of a broad range of deficits with a high degree of individual variation. The phenotype of the disorder includes cognitive disabilities as well as autistic behaviors and epilepsy. Aside from a loss of FMRP expression, the genetic background and environmental factors are emerging as determinants of the disease. However, while residual FMRP expression is known to correlate with the cognitive performance of FXS patients, the impact of individual genes and the relevance of the environment are less well understood (also see the section “Phenotype”). Recent findings indicate that autistic behaviors and epilepsy are influenced by the E/I balance, but not by residual FMRP expression. FXS, Fragile X Syndrome; FMRP, Fragile X Mental Retardation Protein; E/I balance, balance of excitation and inhibition in neuronal networks.
Figure 2FMR1−/y diseases. The scheme shows the relation between microsatellite length (number of repeats) and phenotype. While healthy individuals show 6–44 tandem tracts in the 5′ UTR of their FMR1 gene, FXS patients display more than 200 repeats. Alleles containing 45–54 repeats are classified as intermediate, and 55–200 repeats as pre-mutation alleles. Premutation alleles give rise to a neurodegenerative disorder called FXTAS, which presents with parkinsonism and brain atrophy. FXTAS typically manifests in individuals over the age of 50. FMR1: Fragile X Mental Retardation gene. FMRP: Fragile X Mental Retardation Protein. FXS: Fragile X Syndrome. FXTAS: Fragile X-associated Tremor/Ataxia Syndrome. E/I balance: balance of excitation and inhibition in neuronal networks, UTR: untranslated region. ↓: decreased levels in the diseased condition. ↔ similar levels in normal and diseased conditions. ↑ increased levels in diseased conditions.
Differences between men and mice.
| Category | Mice and men | Reference |
|---|---|---|
| Transposons | The mouse genome contains only 35.5% of transposon derived DNA (humans: >46%), but with 32.4% an higher amount of lineage-specific repeats (humans: 24.4%). | Waterston et al. ( |
| Breakpoint regions | Evolutionary breakpoint regions (intervals between segments of conserved gene order) of mice are mainly enriched for transposable elements of the SINE type (short interspersed nucleotide elements), whereas human breakpoint regions mainly contain the Alu type, a specific subtype of SINE elements. | Schibler et al. ( |
| Transcription | Only 22% of transcription factor footprints and 50% of transcription factor networks are conserved. | Yue et al. ( |
| Although the binding motifs of most sequence-specific transcription factors are conserved, the motifs for co-factors tend to be species specific. | Cheng et al. ( | |
| Immune system | Differences in the immune system include in the balance of leukocyte subsets, in defensins, Toll receptors, inducible NO synthase, Ig subsets, the B cell and T cell signaling pathways, cytokines and cytokine receptors, Th1/Th2 differentiation, co-stimulatory molecule expression and function, antigen-presenting function of endothelial cells, and chemokine and chemokine receptor expression. | reviewed in Mestas and Hughes ( |
| Physiology | Several differences in the physiology and morphology of organs have been reported recently. | e.g.,: Gharib et al. ( |
| Mice are indicated to have higher rates of reactive oxygen species production than humans, however, sufficient original evidence is missing. | Ku et al. ( | |
| The fatty acid composition of the membrane is different in mice and men. | Hulbert ( |
The table summarizes genetic as well as physiological differences between mice and men, which may potentially affect the translation of research results between the two species. While genome studies in mice and humans showed that both mammals mainly differ in terms of gene regulation, differences in the physiology are not well characterized yet.
Fragile X Syndrome and Fragile X-associated Tremor/Ataxia Syndrome model mice.
| MGI | Aliases | Strains | First publication | Further publications and information | |
|---|---|---|---|---|---|
| Fmr1tm1Cgr | 1857169 | Fmr1 KO, Fmr1tm4Cgr, FMRP KO, fmr-tm1Cgr, FraX, FMR1- | Bakker et al. ( | ||
| Fmr1tm1.1Cidz | 3808885 | Fmr1 KO2 | B6.129P2- Fmr1tm1.1Cidz | Mientjes et al. ( | |
| Fmr1tm1Cidz | 3603442 | Fmr1 CKO | Involves: 129S1/Sv* 129X1/SvJ | Koekkoek et al. ( | |
| Fmr1tm2Cgr | 2451086 | CGG(98) Fmr1 CGG KI Fmr1 CGG KI (C57BL/6 congenic) | Bontekoe et al. ( | ||
| Fmr1tm1Usdn | 3711215 | CGG KI, Fmr1PM | Entezam et al. ( | ||
| Fmr1tm1Rbd | 3840615 | Fmr1I304N Fmr1tm1(I304N)Drnl Fmr1tm1(I304N)Rbd | FVB.129-Fmr1tm1Rbd/J B6.129-Fmr1tm1Rbd/J | Zang et al. ( | |
| Tg(Fmr1-EGFP)HP76Gsat | 4847053 | B6;FVB-Tg(Fmr1-EGFP)HP76Gsat/Mmucd | - | - also see: |
The table shows the mouse models most commonly used in .
Figure 3A comparison of FXS in mice and men. The figure summarizes some major differences between FXS model mice and patients. Most differences arise from the development of the cortex in primates, which caused a rewiring inside the cortex as well as between the cortex and the hippocampus (and potentially other brain regions). Consequently, the behavioral phenotype observed in men and mice does not match very well, although the mouse model recapitulates many biochemical aspects of the disease. In addition, the complex genetics of the disease cannot be modeled in mice, probably due to a more relaxed gene expression control in this species.
LTP protocols used in different studies.
| Study | Stimulation | Recording | Study | Stimulation | Recording |
|---|---|---|---|---|---|
| Auerbach and Bear ( | Field recordings | Bostrom et al. ( | Field recordings | ||
| Chen et al. ( | MED64 probe (array) | Godfraind et al. ( | Field recordings | ||
| Harlow et al. ( | Whole cell recordings | Hayashi et al. ( | Field recordings | ||
| Hu et al. ( | Whole-cell recordings | Koga et al. ( | Whole-cell recordings (neurons), multielectrode array (slices) | ||
| Larson et al. ( | Field recordings | Lee et al. ( | Field recording | ||
| Li et al. ( | Field recordings | Martin H. G. S. et al. ( | Whole-cell recordings | ||
| Padmashri et al. ( | Field recordings | Paradee et al. ( | Field recordings | ||
| Shang et al. ( | Field recording, whole-cell recording | Wilson and Cox ( | Field recordings | ||
| Xu et al. ( | Whole-cell recordings | Xu et al. ( | Whole-cell recordings | ||
| Yang et al. ( | Field recordings | Zhang et al. ( | Field recordings | ||
| Zhao et al. ( | Whole-cell recordings |
Literature providing only general information is not included. The data illustrates the variety of induction protocols used to study LTP.
Brain-region bias in FXS research.
| Rescue of behavior | Rescue of neuronal function only | |
|---|---|---|
| Hippocampus based strategies and/or studies | Yan et al. ( | Lauterborn et al. ( |
| Studies including data on several brain regions | Yuskaitis et al. ( | |
| Cortex based strategies and/or studies | Hayashi et al. ( | Henderson et al. ( |
| Amygdala based strategies and/or studies | none | Olmos-Serrano et al. ( |
| Brain regions not specified/studied | Veeraragavan et al. ( |
The table lists all publications that were identified on pubmed or PMC in October 2017, and found to report at least functional rescues of symptoms related to FXS using murine model systems. Studies reporting only morphological rescues were not included. The data show that there is a strong bias toward investigations of hippocampal functions in the literature.